• LICPIC

    LICPIC is part of the AGITG Endorsed Study Model (please click here to find out more)

    Share

Trial Status

Endorsed Studies / Open

Cancer Type

Colorectal Cancer

If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.

PROTOCOL TITLE

A Double-Blind Randomised Placebo-Controlled Trial Assessing the Effect of Peri-Operative Intravenous Lignocaine and Post-Operative Lignocaine Neurovascular Plane Infusion on Natural Killer Cell Function in Laparoscopic Colorectal Cancer Surgery.

Lignocaine Infusion in Colorectal Cancer Patient Immune Cells (LICPIC Study)

PURPOSE OF THE STUDY

The body has many ways of fighting off cancer. One way is a type of white blood cell which recognises and destroys cancer cells, these ells are called natural killer (NK) cells. People with cancer who have more effective NK cells may have less spread of their cancer. A local anaesthetic drug called Lignocaine is very commonly used to numb areas of skin or muscle before or during an operation. It has been shown to help the NK cells to destroy cancer cells.

The study aims to find out if giving local anaesthetic, Lignocaine, into your bloodstream during surgery will improve part of your immune system after surgery.

Eligibility Criteria

Key inclusion criteria

All patients with colorectal cancer undergoing elective or semi-elective laparoscopic colon resection at the John Hunter Hospital and Newcastle Private Hospital.

Key exclusion criteria
  1. Are under 18 years of age
  2. Refuse or are unable to give written informed consent to participate in the study.
  3. Have had previous abdominal surgery where there is a significant chance of the procedure not being able to be completed in a laparoscopic manner, based in the clinical judgement of the operating surgeon
  4. Have severe renal impairment
  5. Receive an epidural, spinal or other neuraxial anaesthetic as determined by the Anaesthetist on day of surgery
  6. Have a planned stoma formation
  7. Have received neoadjuvant chemo-radiotherapy
  8. Have been on immunosuppressive agents in the preceding 8 weeks including glucocorticoids.
  9. Have known stage 4 colorectal cancer disease
  10. Have known immunological disease including leukaemia
  11. Have known allergy or adverse reaction to lignocaine or opioid drugs
  12. Pregnant or lactating
  13. Have a history of arrhythmia or long QT syndrome associated with the drugs used in this trial
  14. Are taking regular opiate narcotics pre-operatively

CONTACT EMAIL

Rosemary.Carroll@health.nsw.gov.au

PRINCIPAL INVESTIGATOR

A/Prof Stephen Smith

DETAILED INFORMATION AVAILABLE

More detailed information available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) please click here.

FUNDING

Colorectal Surgical Society of Australia and New Zealand (CSSANZ)

PATIENTS RECRUITED

Click here to access the table and view recruitment data on all AGITG open trials:

Open Trial Recruitment Table

Participating Centres

New South Wales
John Hunter Hospital
Newcastle Private Hospital

Trial Status

Endorsed Studies / Open

Cancer Type

Colorectal Cancer

If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.

Participating Centres

New South Wales
John Hunter Hospital
Newcastle Private Hospital